Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Solar and Biotech Stocks Are Leading Today’s Gainers

Third quarter results have sent China Finance Online Co. (ADR) (NASDAQ:JRJC) soaring by more than 35%. The web-based financial services company has posted a 75% annual increase in net revenues to $37 million, while net profit was $9.7 million, significantly higher than the $2.4 million reported a year ago.

“We further streamlined our business and freed up additional resources that will allow us to reinvest in and fully focus on developing both iTouGu and Yinglibao. As a result, iTouGu grew rapidly during the quarter,” said Zhiwei Zhao, Chairman and CEO of China Finance Online.

Follow China Fin Online Co Ltd (NASDAQ:JRJC)
Trade (NASDAQ:JRJC) Now!

Only one of the hedge funds that we follow has reported a stake in China Finance Online Co. (ADR) (NASDAQ:JRJC) at the end of the quarter. In its latest 13F filing, Millennium Management reported a holding that amassed 20,257 shares valued at roughly $70,000 at the end of September.

Shareholders of Advaxis, Inc. (NASDAQ:ADXS) are all smiles this morning, after the company announced that the Food and Drug Administration has lifted the ban on its cancer drug candidate and will allow tests to continue. The company also said it agreed to implement some risk-mitigation measures and surveillance measures. The FDA suspended all trials after a cancer patient tested positive for listeria, having taken Advaxis’ cancer drug axalimogene filolisbac and died earlier this year. Shares rose by as much as 38% in early trading.

Follow Advaxis Inc. (NASDAQ:ADXS)
Trade (NASDAQ:ADXS) Now!

Approximately 38% of Advaxis, Inc. (NASDAQ:ADXS)’s stock was held by 21 hedge funds at the end of the third quarter, up from 13 funds at the end of June. Phill Gross and Robert Atchinson are bullish on this stock, having increased their investment by 6% during the quarter to 5.94 million shares.

Acasti Pharma Inc (NASDAQ:ACST) is also among today’s top gainers, after the emerging biotech company received positive feedback from the U.S. Food and Drug Administration regarding its CaPre® development proposal. The company is set to amend its new drug application in order to commence a bridging study. Derived from krill oil, CaPre was designed by Acasti for the treatment of high triglycerides. Shares are currently trading at $2.36, up by 47% from yesterday’s closing price.

Hedge fund presence among the shareholders of Acasti Pharma Inc (NASDAQ:ACST) was insignificant at the end of the third quarter, as only three funds reported a position in this stock. Jim Simons‘ Renaissance Technologies nearly doubled its holding of the stock to 64,100 shares valued at $17,000 at the end of September.

Disclosure: none

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.